Literature DB >> 18955514

Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau.

Johan Ursing1, Poul-Erik Kofoed, Amabelia Rodrigues, Yngve Bergqvist, Lars Rombo.   

Abstract

High chloroquine doses are commonly prescribed in Guinea-Bissau. Double-dose chloroquine has been shown to be more efficacious (92% efficacy) than the standard dose (80% efficacy). However, chloroquine is toxic when overdosed, and it was not known if the high doses prescribed in Guinea-Bissau were taken or whether they caused adverse effects. We aimed to determine the dosage of chloroquine commonly prescribed, the doses commonly taken, and whether concentration-dependent adverse events occurred in routine practice. Chloroquine prescriptions by eight physicians and chloroquine intake by 102 children were recorded. Chloroquine intake and adverse events were assessed by questioning. Chloroquine concentrations in whole blood were measured. The median total chloroquine dose prescribed and that reportedly taken were 81 and 77 mg kg(-1), respectively. The total dose was usually split into two to three daily doses of 6.6 mg kg(-1) each. These were taken unsupervised for a median of 5 days. Forty percent of the study children had chloroquine concentrations in the same range as those found in a previous study in which double the normal dose (50 mg kg(-1)) of chloroquine was taken. Only 3/102 children had Plasmodium falciparum in the blood at the time of diagnosis and treatment. No severe adverse events were reported. No adverse events were associated with higher chloroquine concentrations. High doses of chloroquine are commonly taken and well tolerated in Guinea-Bissau. Malaria diagnostics are poor, and chloroquine is commonly prescribed to children without parasitemia. Use of high-dose chloroquine is concurrent with an exceptionally low prevalence of chloroquine-resistant P. falciparum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955514      PMCID: PMC2612162          DOI: 10.1128/AAC.01111-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan.

Authors:  Abdel-Muhsin A Abdel-Muhsin; Margaret J Mackinnon; Eltayeb Ali; El-Khansaa A Nassir; Suad Suleiman; Salah Ahmed; David Walliker; Hamza A Babiker
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

2.  Chloroquine resistant Plasmodium falciparum malaria in Guinea-Bissau.

Authors:  U Hellgren; I Johansson; F Dias; O Ericsson; J Stenbeck; L Rombo
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jan-Feb       Impact factor: 2.184

3.  Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria.

Authors:  E Pussard; J P Lepers; F Clavier; L Raharimalala; J Le Bras; M Frisk-Holmberg; Y Bergqvist; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.

Authors:  D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

5.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum.

Authors:  John C Wootton; Xiaorong Feng; Michael T Ferdig; Roland A Cooper; Jianbing Mu; Dror I Baruch; Alan J Magill; Xin-Zhuan Su
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

6.  Treatment of uncomplicated malaria in children in Guinea-Bissau with chloroquine, quinine, and sulfadoxine-pyrimethamine.

Authors:  Poul-Erik Kofoed; Fernando Có; Peter Johansson; Francisco Dias; Claudina Cabral; Kathryn Hedegaard; Peter Aaby; Lars Rombo
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 May-Jun       Impact factor: 2.184

7.  The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.

Authors:  S Looareesuwan; N J White; P Chanthavanich; G Edwards; D D Nicholl; C Bunch; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

9.  4-aminoquinolines can be dangerous to your health: chloroquine (Aralen) intoxication.

Authors:  R B Mack
Journal:  N C Med J       Date:  1984-04

10.  Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau.

Authors:  Poul-Erik Kofoed; Francisco Lopez; Peter Johansson; Anita Sandström; Kathryn Hedegaard; Peter Aaby; Lars Rombo
Journal:  Am J Trop Med Hyg       Date:  2002-07       Impact factor: 2.345

View more
  20 in total

Review 1.  Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.

Authors:  Robert L Summers; Megan N Nash; Rowena E Martin
Journal:  Cell Mol Life Sci       Date:  2012-06       Impact factor: 9.261

2.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012.

Authors:  Irina Tatiana Jovel; Poul-Erik Kofoed; Lars Rombo; Amabelia Rodrigues; Johan Ursing
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

4.  Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.

Authors:  Brioni R Moore; Madhu Page-Sharp; Jillian R Stoney; Kenneth F Ilett; Jeffrey D Jago; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

5.  Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.

Authors:  Johan Ursing; Poul-Erik Kofoed; Amabelia Rodrigues; Daniel Blessborn; Rikke Thoft-Nielsen; Anders Björkman; Lars Rombo
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

6.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.

Authors:  Allison M Stickles; Li-Min Ting; Joanne M Morrisey; Yuexin Li; Michael W Mather; Erin Meermeier; April M Pershing; Isaac P Forquer; Galen P Miley; Sovitj Pou; Rolf W Winter; David J Hinrichs; Jane X Kelly; Kami Kim; Akhil B Vaidya; Michael K Riscoe; Aaron Nilsen
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

8.  High-Dose Chloroquine for Uncomplicated Plasmodium falciparum Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children.

Authors:  Johan Ursing; Lars Rombo; Staffan Eksborg; Lena Larson; Anita Bruvoll; Joel Tarning; Amabelia Rodrigues; Poul-Erik Kofoed
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

9.  Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan.

Authors:  Natasha Howard; Naeem Durrani; Sanda Sanda; Khalid Beshir; Rachel Hallett; Mark Rowland
Journal:  Malar J       Date:  2011-06-23       Impact factor: 2.979

10.  No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used.

Authors:  Johan Ursing; Poul-Erik Kofoed; Amabelia Rodrigues; Lars Rombo
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.